There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

WeightWatchers will begin selling compounded alternatives to certain weight-loss drugs that are experiencing shortages. Why it matters: Federal law allows companies to sell compounded versions of drugs that are on the FDA's shortages list — which has led to a surge of copycats to the newly popular class of GLP-1 injections.

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such as Wegovy and Ozempic. The survey was conducted by Morning Consult for the Physicians Committee for Responsible Medicine,

Lots of people want to lose weight but they don't necessarily want to take regular injections to do it. That's the finding of a new national survey. It fou

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.

The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ingredient of Eli Lilly's (NYSE:LLY) diabetes therapy Mounjaro and weight loss therapy Zepbound,